These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16815295)

  • 21. Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival.
    Liu L; Wu C; Wang Y; Zhong R; Duan S; Wei S; Lin S; Zhang X; Tan W; Yu D; Nie S; Miao X; Lin D
    J Thorac Oncol; 2011 Nov; 6(11):1793-800. PubMed ID: 21841506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mdm2 overexpression and p73 loss exacerbate genomic instability and dampen apoptosis, resulting in B-cell lymphoma.
    Riley MF; You MJ; Multani AS; Lozano G
    Oncogene; 2016 Jan; 35(3):358-65. PubMed ID: 25915849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Significance of MDM2 protein in the cell cycle].
    Szemraj J; Rozpończyk E; Bartkowiak J; Greger J; Oszajca K
    Postepy Biochem; 2005; 51(1):44-51. PubMed ID: 16209341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p53, p63 and p73 expression in squamous cell carcinomas of the head and neck and their response to cisplatin exposure.
    Gwosdz C; Balz V; Scheckenbach K; Bier H
    Adv Otorhinolaryngol; 2005; 62():58-71. PubMed ID: 15608418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. P53 and p73 differ in their ability to inhibit glucocorticoid receptor (GR) transcriptional activity.
    Zhang L; Nie L; Maki CG
    Mol Cancer; 2006 Dec; 5():68. PubMed ID: 17150106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MDM2 and MDMX can interact differently with ARF and members of the p53 family.
    Wang X; Arooz T; Siu WY; Chiu CH; Lau A; Yamashita K; Poon RY
    FEBS Lett; 2001 Feb; 490(3):202-8. PubMed ID: 11223036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of p73 gene overexpression on apoptosis and chemosensitivity of human lung adenocarcinoma cell line A549.
    He Y; Fan SZ; Jiang YG
    Ai Zheng; 2006 Aug; 25(8):925-32. PubMed ID: 16965670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. P53 family: at the crossroads in cancer therapy.
    Alsafadi S; Tourpin S; André F; Vassal G; Ahomadegbe JC
    Curr Med Chem; 2009; 16(32):4328-44. PubMed ID: 19754415
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p73 protein expression correlates with radiation-induced apoptosis in the lack of p53 response to radiation therapy for cervical cancer.
    Wakatsuki M; Ohno T; Iwakawa M; Ishikawa H; Noda S; Ohta T; Kato S; Tsujii H; Imai T; Nakano T
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1189-94. PubMed ID: 18313527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting of p53 and its homolog p73 by protoporphyrin IX.
    Sznarkowska A; Maleńczyk K; Kadziński L; Bielawski KP; Banecki B; Zawacka-Pankau J
    FEBS Lett; 2011 Jan; 585(1):255-60. PubMed ID: 21146529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of p53 sequence elements that are required for MDM2-mediated nuclear export.
    Gu J; Nie L; Wiederschain D; Yuan ZM
    Mol Cell Biol; 2001 Dec; 21(24):8533-46. PubMed ID: 11713288
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p53 and Mdm2: an auld alliance.
    Vigneron A; Vousden KH
    Cell Cycle; 2010 Mar; 9(5):865-6. PubMed ID: 20348845
    [No Abstract]   [Full Text] [Related]  

  • 34. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function.
    Azmi AS; Aboukameel A; Banerjee S; Wang Z; Mohammad M; Wu J; Wang S; Yang D; Philip PA; Sarkar FH; Mohammad RM
    Eur J Cancer; 2010 Apr; 46(6):1122-31. PubMed ID: 20156675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MDM2 mediates p73 ubiquitination: a new molecular mechanism for suppression of p73 function.
    Wu H; Leng RP
    Oncotarget; 2015 Aug; 6(25):21479-92. PubMed ID: 26025930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential regulation of p73 variants in response to cisplatin treatment in SH-SY5Y neuroblastoma cells.
    Million K; Horvilleur E; Goldschneider D; Agina M; Raguénez G; Tournier F; Bénard J; Douc-Rasy S
    Int J Oncol; 2006 Jul; 29(1):147-54. PubMed ID: 16773194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation and activation of p53 and its family members.
    Lohrum MA; Vousden KH
    Cell Death Differ; 1999 Dec; 6(12):1162-8. PubMed ID: 10637431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1, and Caspase-9/-3 activation.
    Sørensen BH; Nielsen D; Thorsteinsdottir UA; Hoffmann EK; Lambert IH
    Am J Physiol Cell Physiol; 2016 Jun; 310(11):C857-73. PubMed ID: 26984736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ruthenium (II)-derived organometallic compounds induce cytostatic and cytotoxic effects on mammalian cancer cell lines through p53-dependent and p53-independent mechanisms.
    Gaiddon C; Jeannequin P; Bischoff P; Pfeffer M; Sirlin C; Loeffler JP
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1403-11. PubMed ID: 16169939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of p53 and its homologues in primary and recurrent squamous cell carcinomas of the head and neck.
    Weber A; Bellmann U; Bootz F; Wittekind C; Tannapfel A
    Int J Cancer; 2002 May; 99(1):22-8. PubMed ID: 11948487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.